National investment fraud lawyers KlaymanToskes continues investigating Clovis Oncology, Inc., a now-bankrupt pharmaceutical company, on behalf of Clovis’s shareholders and unsecured noteholders, who are now owed more than $400 million.
After filing for Chapter 11 bankruptcy in December 2022 and having its common stock delisted from the NASDAQ, Clovis Oncology reported a net worth of -$564,021,041 in April 2023, and recently sold the majority of its remaining assets, including its cancer drug Rubraca.
Investors that purchased unsuitable investments in Clovis Oncology Inc. through JP Morgan Securities, Credit Suisse, BofA Securities, Leerink Swann, or any other full-service brokerage firm, may hold their firm and broker/financial advisor liable for their losses in a FINRA arbitration claim.
If you suffered losses in Clovis Oncology, Inc., contact attorney Lawrence L. Klayman at 888-997-9956 or by email at lawrence@klaymantoskes.com to discuss your recovery options. We do not collect attorney’s fees unless we are able to obtain a financial recovery for you.
KlaymanToskes is a leading national securities fraud law firm that represents the interests of investors throughout the world who have suffered losses due to broker misconduct, investment fraud, and securities violations.
The articles linked below contain important information relating to KlaymanToskes’ investigations of Clovis Oncology, Inc.:
If you suffered losses in Clovis Oncology at a full-service brokerage firm, contact KlaymanToskes at 888-997-9956 or fill out a short contact form for a free and confidential consultation.
The firm has helped recover over $600 million* for investors, and can help you determine if your loss is due to financial advisor misconduct, unsuitable investment advice, and/or other securities violations.
*Exclusive of attorneys fees and costs.
As an investor, there are a few signs that you should look out for if you believe you have a claim against your broker/advisor for unsuitable investment recommendations in Clovis Oncology. These signs could potentially indicate misconduct, negligence, or investment fraud. Investors are encouraged to contact our firm immediately if you have experienced any of the following:
Some investors have close relationships with their brokers due to the time and trust built over the course of their investment relationship. However, it is crucial to remember that financial decisions should be based on careful analysis and due diligence rather than solely relying on personal relationships.
Engaging the services of an experienced securities attorney to evaluate your specific circumstances is strongly advised. At KlaymanToskes, our team of experienced securities attorneys has a deep understanding of this complex area of law, allowing us to provide invaluable insight and tailored guidance that directly addresses your individual needs.
If you purchased unsuitable Clovis Oncology investments through JPMorgan Securities, Credit Suisse, Leerink Swann, or any other full-service brokerage firm, and suffered significant losses, contact KlaymanToskes at 888-997-9956 or fill out a short contact form for a free and confidential consultation. Disclosure: Investors that had self-directed accounts who did not rely on the advice of a financial advisor need not call.